Topic: Using QSP in Development Decisions

Updating Development Decisions With Early Clinical Data

Using Predicted Heterogeneity to Define Trial Enrichment

Valuing New Experiments by Their Potential to Change a Decision

Testing Whether a Target Is Causal or Merely Correlated

Stress-Testing Decisions Against Model Uncertainty

Setting Quantitative Go Or No-Go Criteria for Early Trials

Selecting a Target Modulation Goal From Exposure-Response Predictions

Selecting Pharmacodynamic Biomarkers for Mechanism Discrimination

Ranking Targets by Mechanistic Reversibility and Tissue Reach

Mapping QSP Outputs to Development Decision Rules